AstraZeneca Drafts Plan to Spin Off China Business, FT Says
- Astra considering move amid geopolitical tensions: FT sources
- UK pharmaceutical company has long invested in the region
This article is for subscribers only.
AstraZeneca Plc has drawn up plans to possibly spin off its China business and list it separately in Hong Kong, the Financial Times reported, citing people familiar with the talks.
The drugmaker began discussing the idea with bankers several months ago as geopolitical tensions grew, the newspaper said, citing three people familiar with the matter. The entity could also be listed in Shanghai, one of the people said.